Metabolic drugs in anti-ischemic therapy

Abstract

The first drugs for anti-ischemic therapy were vitamins of group B, but their effectiveness was refuted in clinical trials. The next drug was trimetazidine, since it has a high cytoprotective effect. This drug is especially effective in patients with stable angina. But thiotriazoline is a new anti-ischemic drug that includes anti-ischemic, metabolic and antioxidant activity with minimal side effects. Summing up, given the good tolerability, efficacy and safety, thiotriazoline can be recommended as a remedy of metabolic therapy for the treatment of IHD in the elderly.

Description

Citation

Zakharenkova A. Metabolic drugs in anti-ischemic therapy / A. Zakharenkova // Science and Life : Proceedings of articles the international scientific conference, Skleněný Můstek, Karlovy Vary, Czech Republic, 16–17 November 2017. – Karlovy Vary, 2017. – P. 59–64.

Endorsement

Review

Supplemented By

Referenced By